Infectious Disease Therapeutics Market Report: Size, Share and Outlook by 2030

The market for infectious disease therapeutics was valued at approximately US$ 119,708.77 million in 2022 and is projected to grow to US$ 167,883.93 million by 2030. This growth represents an estimated CAGR of 4.3% from 2022 to 2030.

Infectious diseases are transmitted between individuals through both direct and indirect contact. To combat these diseases, patients are required to use medications that possess anti-infective properties. The primary culprits behind these illnesses include various pathogens such as bacteria, fungi, viruses, and parasites. The treatment approach typically involves targeting the specific organism responsible for the infection while also bolstering the host's immune response. The increasing geriatric population presents a substantial opportunity for the infectious disease therapeutics market to expand in the upcoming years.

Research and development (R&D) play a pivotal role in the operations of biopharmaceutical and pharmaceutical companies. Through R&D, these companies can introduce new products that hold significant medical and commercial promise across a range of therapeutic applications.

Several notable projects have been funded by manufacturers in this sector:

• In June 2022, GSK plc committed US$ 1.21 billion (approximately ?1 billion) over a decade to enhance R&D focused on infectious diseases. This investment aims to foster innovation in areas such as malaria, tuberculosis, and HIV, with additional focus on Neglected Tropical Diseases and combating antimicrobial resistance.


• In March 2022, the Canadian government announced a funding of US$ 48.07 million (CAD 60 million) to support the Global Fund's COVID-19 Response Mechanism (C19RM). This funding was welcomed by the Global Fund to Fight AIDS, Tuberculosis, and Malaria, as it will help provide essential diagnostic tools, medical oxygen, and personal protective equipment (PPE) to low- and middle-income countries.


• In September 2021, the Biden-Harris Administration revealed a US$ 2.1 billion investment aimed at improving infection prevention and control measures within the US public health and healthcare systems. This funding is directed towards state, municipal, and territorial health agencies, as well as other organizations involved in managing infectious diseases in the United States, facilitated through the Centers for Disease Control and Prevention (CDC).

Consequently, the increasing emphasis on R&D and financial backing in the field of infectious disease therapeutics is propelling market growth.

Insights by Product in the Infectious Disease Therapeutics Market

The infectious disease therapeutics market is categorized by drug type into several classes: anti-viral, anti-bacterial, anti-fungal, and others. In 2022, the anti-viral segment dominated the market share, while the anti-bacterial segment is anticipated to exhibit the highest CAGR from 2022 to 2030. Anti-viral medications are those approved by the US Food and Drug Administration (FDA) for the treatment of viral infections, targeting specific stages of the viral life cycle. These medications can be utilized for prevention, treatment, suppression, or management of overt disease.

Insights by Indication in the Infectious Disease Therapeutics Market

When segmented by indication, the infectious disease therapeutics market includes categories such as HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held the largest market share in 2022 and is expected to achieve the highest CAGR from 2022 to 2030. HIV compromises the immune system by destroying crucial cells that are essential for fighting infections and diseases. Certain demographics in the US are at a higher risk of contracting HIV due to factors such as sexual behavior and the number of partners. Additionally, the risk of infection post-surgery can increase due to the immune suppression caused by HIV. The prevalence of HIV infections has been on the rise in recent years, but the life expectancy of individuals living with HIV and AIDS has significantly improved since the advent of antiretroviral therapy (ART).

Key sources of information for the report on the infectious disease therapeutics market include the National Institute of Health, the Centers for Disease Control and Prevention, and various studies on healthcare-associated infections.